- Investing Ideas
- Pakistani Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Pakistani Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
GlaxoSmithKline Pakistan
Market Cap: PK₨117.2b
Operates as a biopharma company in Pakistan.
GLAXO
PK₨368.11
7D
13.5%
1Y
-17.4%
Hoechst Pakistan
Market Cap: PK₨38.0b
Together with its subsidiary, manufactures, sells, and trades in pharmaceutical and related products in Pakistan, Afghanistan, and internationally.
HPL
PK₨3,942.00
7D
1.0%
1Y
18.7%